Association of CYP3A5*3 and CYP3A5*6 polymorphisms with breast cancer risk

Current Trends in Biotechnology and Pharmacy

Volumn 3, Issue 2, 2009, Pages 181-187

  Surekha, D ^a   Sailaja, K ^a   Nageswara Rao, D ^a   Padma, T ^a   Raghunadharao, D ^b   Vishnupriya, Satti ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Polymorphisms; Receptor status

Indexed keywords

CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 66549095184     PISSN: 09738916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Paulussen A., Lavrijsen K., Bohets H., Hendrickx J., Verhasselt P., Luyten W., Konings F. and Armstrong M. (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics, 10: 415-424.
2. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., Deglmann CJ., Burk O., Buntefuss D., Escher S., Bishop C., Koebe HG., Brinkmann U., Klenk HP., Kleine K., Meyer UA. and Wojnowski L. (2001). Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11: 111-121.
3. Jounaidi Y., Guzelian PS., Maurel P. and Vilarem MJ. (1994). Sequence of the 5-prime-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophys Res Commun, 205: 1741-1747.
4. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins PB., Daly A., Wrighton SA., Hall SD., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski MS. and Schuetz E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Gene, 27: 383-391.
5. Park SY., Kang YS., Jeong MS., Yoon HK. and Han KO. (2008). Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. Pharmacogenetics, 33 (1): 61-65.
6. Liu TC., Lin SF., Chen TP. and Chang JG. (2001). Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep,9(2):327-9.
7. Nuremberg JI. and Lahari D K Jr. (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood RFLP studies. Nucleic Acid Research, 19: 5444.
8. Ta-Chih Liu., Sheng-Fung Lin., Tyen-Po Chen. and Jan-Goeth Chang. (2002). Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncology reports, 9: 327-329.
9. Gillam EMJ., Guo Z., Ueng YF., Yamazaki H., Cock I., Reilly PE. and Hooper WD. and Guengerich FP. (1995). Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral charecterization, reconstitution condition and catalytic activities. Arch Biochem Biophys, 318: 374-384.
10. Wojnowski L., Hustert E., Klein K., Goldhammer M., Haberl M., Kiechheiner J., Koch L., Klattig J., Zanger U. and Brock moller J. Re. (2002). Modification of clinical presentation of prostrate tumors by a novel genetic variant in CYP2A4. J Natl Cancer Inst, 94:630-631.
11. Gervasini G., Marti E., Ladero M., Pizarro R., Sastre J., Martinez C., Gracia M., Diaz-Rubio M. and Agundez AG. (2007). Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer, 7: 118.
12. Wilkinson GR. (2004). Genetic variabilityin cytochrome P4503A5 and invivo cytochrome cytochrome P4503A activity: some answers but still questions. Clin Pharmacol Ther, 76:99-103.
13. Nogal A., Coelho A., Araujo A., Azevedo I., Faria A., Soares M., Catarino R. and Medeiros R. (2007) CYP3A5*3 genotypes and advanced non-small cell lung cancer development. Journal of clinical Oncology, 25(18S): 21030.